We’re pleased to announce that posters presented at the 2019 National Lipid Association (NLA) Scientific Sessions are now available for viewing online!
The NLA accepted over 85 abstracts covering topics across the spectrum of clinical lipidology and cardiovascular disease prevention. This year’s abstracts topics included:
An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.
The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.
Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.
Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.
Among the results presented today:
.jpg)
.png)
